FATE-NK100, a natural killer cell immunotherapy, induced stable disease in one of the first two heavily treated ovarian cancer patients in a Phase 1 trial. No dose-limiting toxicities have been reported so far, Fate Therapeutics announced. The findings were recently revealed during the oral presentation, “Novel strategies to activate Adaptive NK cells and Make them antigen specific,” at